In the light of previous results that silence of c‐MET and/or BRCA1/2 sensitizes AGS and Hs746T cells to NU1025 treatment, we continue with the investigation of an additive effect in co‐inhibition of c‐MET (5 μmol/L SU11274) and PARP (5 μmol/L NU1025) inhibitor in order to further reduce the proliferation of GC cell lines. Here, MET is linked to gastric cancer.